Semin Respir Crit Care Med 2019; 40(02): 235-254
DOI: 10.1055/s-0039-1688448
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Pulmonary and Bronchiolar Involvement in Sjogren's Syndrome

Augustine Chung
1   Division of Pulmonary and Critical Care Medicine, Clinical Immunology, and Allergy, David Geffen School of Medicine at UCLA, Los Angeles, California
,
May Lin Wilgus
1   Division of Pulmonary and Critical Care Medicine, Clinical Immunology, and Allergy, David Geffen School of Medicine at UCLA, Los Angeles, California
,
Gregory Fishbein
2   Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
,
Joseph P. Lynch III
1   Division of Pulmonary and Critical Care Medicine, Clinical Immunology, and Allergy, David Geffen School of Medicine at UCLA, Los Angeles, California
› Author Affiliations
Further Information

Publication History

Publication Date:
28 May 2019 (online)

Abstract

Sjogren's syndrome (SS) is a chronic autoimmune disease characterized by mononuclear cells (principally lymphocytes) infiltrating exocrine glands (e.g., salivary and lacrimal glands), leading to destruction of exocrine epithelial cells and dryness of mucosal surfaces. Cardinal symptoms are dry eyes (xerophthalmia) and dry mouth (xerostomia). Extraglandular sites are affected in 30 to 40% of cases of SS (particularly neurological, kidneys, skin, and lungs). B cell hyperactivity, autoantibody production, and hypergammaglobulinemia are cardinal features of SS. Primary SS is not associated with other autoimmune diseases. However, SS can complicate diverse autoimmune disorders (particularly systemic lupus erythematosus, rheumatoid arthritis, and scleroderma); this form is termed “secondary SS.” Pulmonary involvement is usually not a dominant feature of SS, but may be severe in some cases. In this review, we discuss specific tracheal, bronchiolar, and pulmonary complications of SS including xerotrachea, bronchiolitis, bronchiectasis, interstitial lung disease, nonspecific interstitial pneumonia, usual interstitial pneumonia, lymphoid interstitial pneumonia, organizing pneumonia, acute fibrinous and organizing pneumonia, pulmonary cysts, pleural effusions, pulmonary amyloidosis, and bronchus- or lung-associated lymphomas.

 
  • References

  • 1 Luciano N, Valentini V, Calabrò A. , et al. One year in review 2015: Sjögren's syndrome. Clin Exp Rheumatol 2015; 33 (02) 259-271
  • 2 van der Heijden EHM, Kruize AA, Radstake TRDJ, van Roon JAG. Optimizing conventional DMARD therapy for Sjögren's syndrome. Autoimmun Rev 2018; 17 (05) 480-492
  • 3 Ramos-Casals M, Brito-Zerón P, Seror R. , et al; EULAR Sjögren Syndrome Task Force. Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology (Oxford) 2015; 54 (12) 2230-2238
  • 4 Hernández-Molina G, Zamora-Legoff T, Romero-Díaz J. , et al. Predicting Sjögren's syndrome in patients with recent-onset SLE. Rheumatology (Oxford) 2013; 52 (08) 1438-1442
  • 5 He J, Ding Y, Feng M. , et al. Characteristics of Sjögren's syndrome in rheumatoid arthritis. Rheumatology (Oxford) 2013; 52 (06) 1084-1089
  • 6 Theander E, Jacobsson LT. Relationship of Sjögren's syndrome to other connective tissue and autoimmune disorders. Rheum Dis Clin North Am 2008; 34 (04) 935-947 , viii–ix
  • 7 Flament T, Bigot A, Chaigne B, Henique H, Diot E, Marchand-Adam S. Pulmonary manifestations of Sjögren's syndrome. Eur Respir Rev 2016; 25 (140) 110-123
  • 8 Kreider M, Highland K. Pulmonary involvement in Sjögren syndrome. Semin Respir Crit Care Med 2014; 35 (02) 255-264
  • 9 Cornec D, Devauchelle-Pensec V, Tobón GJ, Pers JO, Jousse-Joulin S, Saraux A. B cells in Sjögren's syndrome: from pathophysiology to diagnosis and treatment. J Autoimmun 2012; 39 (03) 161-167
  • 10 Teos LY, Alevizos I. Genetics of Sjögren's syndrome. Clin Immunol 2017; 182: 41-47
  • 11 Reksten TR, Lessard CJ, Sivils KL. Genetics in Sjögren syndrome. Rheum Dis Clin North Am 2016; 42 (03) 435-447
  • 12 Lessard CJ, Li H, Adrianto I. , et al; UK Primary Sjögren's Syndrome Registry. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome. Nat Genet 2013; 45 (11) 1284-1292
  • 13 Altorok N, Coit P, Hughes T. , et al. Genome-wide DNA methylation patterns in naive CD4+ T cells from patients with primary Sjögren's syndrome. Arthritis Rheumatol 2014; 66 (03) 731-739
  • 14 Nordmark G, Wang C, Vasaitis L. , et al; UK Primary Sjögren's Syndrome Registry. Association of genes in the NF-κB pathway with antibody-positive primary Sjögren's syndrome. Scand J Immunol 2013; 78 (05) 447-454
  • 15 Fox RI. Sjögren's syndrome. Lancet 2005; 366 (9482): 321-331
  • 16 Maślińska M, Przygodzka M, Kwiatkowska B, Sikorska-Siudek K. Sjögren's syndrome: still not fully understood disease. Rheumatol Int 2015; 35 (02) 233-241
  • 17 Lucchesi D, Bombardieri M. The role of viruses in autoreactive B cell activation within tertiary lymphoid structures in autoimmune diseases. J Leukoc Biol 2013; 94 (06) 1191-1199
  • 18 Croia C, Astorri E, Murray-Brown W. , et al. Implication of Epstein-Barr virus infection in disease-specific autoreactive B cell activation in ectopic lymphoid structures of Sjögren's syndrome. Arthritis Rheumatol 2014; 66 (09) 2545-2557
  • 19 Hillen MR, Ververs FA, Kruize AA, Van Roon JA. Dendritic cells, T-cells and epithelial cells: a crucial interplay in immunopathology of primary Sjögren's syndrome. Expert Rev Clin Immunol 2014; 10 (04) 521-531
  • 20 Alunno A, Petrillo MG, Nocentini G. , et al. Characterization of a new regulatory CD4+ T cell subset in primary Sjögren's syndrome. Rheumatology (Oxford) 2013; 52 (08) 1387-1396
  • 21 Jin L, Yu D, Li X. , et al. CD4+CXCR5+ follicular helper T cells in salivary gland promote B cells maturation in patients with primary Sjogren's syndrome. Int J Clin Exp Pathol 2014; 7 (05) 1988-1996
  • 22 Szabo K, Papp G, Barath S, Gyimesi E, Szanto A, Zeher M. Follicular helper T cells may play an important role in the severity of primary Sjögren's syndrome. Clin Immunol 2013; 147 (02) 95-104
  • 23 Kyriakidis NC, Kapsogeorgou EK, Gourzi VC, Konsta OD, Baltatzis GE, Tzioufas AG. Toll-like receptor 3 stimulation promotes Ro52/TRIM21 synthesis and nuclear redistribution in salivary gland epithelial cells, partially via type I interferon pathway. Clin Exp Immunol 2014; 178 (03) 548-560
  • 24 Yao Y, Liu Z, Jallal B, Shen N, Rönnblom L. Type I interferons in Sjögren's syndrome. Autoimmun Rev 2013; 12 (05) 558-566
  • 25 Mavragani CP, Moutsopoulos HM. Sjögren's syndrome. Annu Rev Pathol 2014; 9: 273-285
  • 26 Nezos A, Gravani F, Tassidou A. , et al. Type I and II interferon signatures in Sjogren's syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis. J Autoimmun 2015; 63: 47-58
  • 27 Hernández-Molina G, Nuñez-Alvarez C, Avila-Casado C. , et al. Usefulness of IgA anti-α-fodrin antibodies in combination with rheumatoid factor and/or antinuclear antibodies as substitute immunological criterion in Sjögren syndrome with negative anti-SSA/SSB antibodies. J Rheumatol 2016; 43 (10) 1852-1857
  • 28 Theander E, Jonsson R, Sjöström B, Brokstad K, Olsson P, Henriksson G. Prediction of Sjögren's syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling. Arthritis Rheumatol 2015; 67 (09) 2427-2436
  • 29 Fayyaz A, Kurien BT, Scofield RH. Autoantibodies in Sjögren's syndrome. Rheum Dis Clin North Am 2016; 42 (03) 419-434
  • 30 Maślińska M, Mańczak M, Wojciechowska B, Kwiatkowska B. The prevalence of ANA antibodies, anticentromere antibodies, and anti-cyclic citrullinated peptide antibodies in patients with primary Sjögren's syndrome compared to patients with dryness symptoms without primary Sjögren's syndrome confirmation. Reumatologia 2017; 55 (03) 113-119
  • 31 Ramos-Casals M, Brito-Zerón P, Solans R. , et al; SS Study Group; Autoimmune Diseases Study Group (GEAS) of the Spanish Society of Internal Medicine (SEMI). Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology (Oxford) 2014; 53 (02) 321-331
  • 32 Baldini C, Mosca M, Della Rossa A. , et al. Overlap of ACA-positive systemic sclerosis and Sjögren's syndrome: a distinct clinical entity with mild organ involvement but at high risk of lymphoma. Clin Exp Rheumatol 2013; 31 (02) 272-280
  • 33 Defendenti C, Atzeni F, Spina MF. , et al. Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. Autoimmun Rev 2011; 10 (03) 150-154
  • 34 Lee LA. The clinical spectrum of neonatal lupus. Arch Dermatol Res 2009; 301 (01) 107-110
  • 35 Beckman KA, Luchs J, Milner MS. Making the diagnosis of Sjögren's syndrome in patients with dry eye. Clin Ophthalmol 2015; 10: 43-53
  • 36 Suresh L, Malyavantham K, Shen L, Ambrus Jr JL. Investigation of novel autoantibodies in Sjogren's syndrome utilizing Sera from the Sjogren's international collaborative clinical alliance cohort. BMC Ophthalmol 2015; 15: 38
  • 37 Salliot C, Gottenberg JE, Bengoufa D, Desmoulins F, Miceli-Richard C, Mariette X. Anticentromere antibodies identify patients with Sjögren's syndrome and autoimmune overlap syndrome. J Rheumatol 2007; 34 (11) 2253-2258
  • 38 He J, Guo JP, Ding Y. , et al. Diagnostic significance of measuring antibodies to cyclic type 3 muscarinic acetylcholine receptor peptides in primary Sjogren's syndrome. Rheumatology (Oxford) 2011; 50 (05) 879-884
  • 39 Patel R, Shahane A. The epidemiology of Sjögren's syndrome. Clin Epidemiol 2014; 6: 247-255
  • 40 Retamozo S, Akasbi M, Brito-Zerón P. , et al. Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sjögren's syndrome. Clin Exp Rheumatol 2012; 30 (05) 686-692
  • 41 Wolska N, Rybakowska P, Rasmussen A. , et al. Brief report: patients with primary Sjögren's syndrome who are positive for autoantibodies to tripartite motif-containing protein 38 show greater disease severity. Arthritis Rheumatol 2016; 68 (03) 724-729
  • 42 Quartuccio L, Baldini C, Bartoloni E. , et al. Anti-SSA/SSB-negative Sjögren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. Autoimmun Rev 2015; 14 (11) 1019-1022
  • 43 Helmick CG, Felson DT, Lawrence RC. , et al; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008; 58 (01) 15-25
  • 44 Qin B, Wang J, Yang Z. , et al. Epidemiology of primary Sjögren's syndrome: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74 (11) 1983-1989
  • 45 Nannini C, Jebakumar AJ, Crowson CS, Ryu JH, Matteson EL. Primary Sjogren's syndrome 1976-2005 and associated interstitial lung disease: a population-based study of incidence and mortality. BMJ Open 2013; 3 (11) e003569
  • 46 Birlik M, Akar S, Gurler O. , et al. Prevalence of primary Sjogren's syndrome in Turkey: a population-based epidemiological study. Int J Clin Pract 2009; 63 (06) 954-961
  • 47 Maldini C, Seror R, Fain O. , et al. Epidemiology of primary Sjögren's syndrome in a French multiracial/multiethnic area. Arthritis Care Res (Hoboken) 2014; 66 (03) 454-463
  • 48 Gøransson LG, Haldorsen K, Brun JG. , et al. The point prevalence of clinically relevant primary Sjögren's syndrome in two Norwegian counties. Scand J Rheumatol 2011; 40 (03) 221-224
  • 49 Alamanos Y, Tsifetaki N, Voulgari PV, Venetsanopoulou AI, Siozos C, Drosos AA. Epidemiology of primary Sjögren's syndrome in north-west Greece, 1982-2003. Rheumatology (Oxford) 2006; 45 (02) 187-191
  • 50 Ramos-Casals M, Solans R, Rosas J. , et al; GEMESS Study Group. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 2008; 87 (04) 210-219
  • 51 García-Carrasco M, Ramos-Casals M, Rosas J. , et al. Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore) 2002; 81 (04) 270-280
  • 52 Vivino FB. Sjogren's syndrome: clinical aspects. Clin Immunol 2017; 182: 48-54
  • 53 Luemsamran P, Rootman J, White VA, Nassiri N, Heran MKS. The role of biopsy in lacrimal gland inflammation: a clinicopathologic study. Orbit 2017; 36 (06) 411-418
  • 54 Brito-Zerón P, Kostov B, Fraile G. , et al; SS Study Group GEAS-SEMI. Characterization and risk estimate of cancer in patients with primary Sjögren syndrome. J Hematol Oncol 2017; 10 (01) 90
  • 55 Solans-Laqué R, López-Hernandez A, Bosch-Gil JA, Palacios A, Campillo M, Vilardell-Tarres M. Risk, predictors, and clinical characteristics of lymphoma development in primary Sjögren's syndrome. Semin Arthritis Rheum 2011; 41 (03) 415-423
  • 56 Vitali C, Bombardieri S, Jonsson R. , et al; European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61 (06) 554-558
  • 57 Shiboski SC, Shiboski CH, Criswell L. , et al; Sjögren's International Collaborative Clinical Alliance (SICCA) Research Groups. American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012; 64 (04) 475-487
  • 58 Goules AV, Tzioufas AG, Moutsopoulos HM. Classification criteria of Sjögren's syndrome. J Autoimmun 2014; 48-49: 42-45
  • 59 Hernández-Molina G, Avila-Casado C, Nuñez-Alvarez C. , et al. Utility of the American-European Consensus Group and American College of Rheumatology Classification Criteria for Sjögren's syndrome in patients with systemic autoimmune diseases in the clinical setting. Rheumatology (Oxford) 2015; 54 (03) 441-448
  • 60 Shiboski CH, Shiboski SC, Seror R. , et al; International Sjögren's Syndrome Criteria Working Group. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 2017; 76 (01) 9-16
  • 61 Lee J, Koh JH, Kim JW. , et al. Performance of the 2016 ACR-EULAR classification criteria for primary Sjogren's syndrome in a Korean cohort. Rheumatol Int 2018; 38 (09) 1651-1660
  • 62 Billings M, Amin Hadavand M, Alevizos I. Comparative analysis of the 2016 ACR-EULAR and the 2002 AECG classification criteria for Sjögren's syndrome: findings from the NIH cohort. Oral Dis 2018; 24 (1-2): 184-190
  • 63 Brito-Zerón P, Theander E, Baldini C. , et al; EULAR Sjögren Syndrome Task Force. Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations. Expert Rev Clin Immunol 2016; 12 (02) 137-156
  • 64 Tsuboi H, Hagiwara S, Asashima H. , et al. Comparison of performance of the 2016 ACR-EULAR classification criteria for primary Sjögren's syndrome with other sets of criteria in Japanese patients. Ann Rheum Dis 2017; 76 (12) 1980-1985
  • 65 Mathews PM, Hahn S, Hessen M. , et al. Ocular complications of primary Sjögren syndrome in men. Am J Ophthalmol 2015; 160 (03) 447-452.e1
  • 66 Fernandez Castro M, Sánchez-Piedra C, Andreu JL, Martínez Taboada V, Olivé A, Rosas J. ; SJOGRENSER Group, part of the Spanish Society of Rheumatology Systemic Autoimmune Diseases Study Group (EASSER). Factors associated with severe dry eye in primary Sjögren's syndrome diagnosed patients. Rheumatol Int 2018; 38 (06) 1075-1082
  • 67 Chung JK, Kim MK, Wee WR. Prognostic factors for the clinical severity of keratoconjunctivitis sicca in patients with Sjogren's syndrome. Br J Ophthalmol 2012; 96 (02) 240-245
  • 68 Shih KC, Lun CN, Jhanji V, Thong BY, Tong L. Systematic review of randomized controlled trials in the treatment of dry eye disease in Sjogren syndrome. J Inflamm (Lond) 2017; 14: 26
  • 69 Qin R, Steel A, Fazel N. Oral mucosa biology and salivary biomarkers. Clin Dermatol 2017; 35 (05) 477-483
  • 70 Spijkervet FK, Haacke E, Kroese FG, Bootsma H, Vissink A. Parotid gland biopsy, the alternative way to diagnose Sjögren syndrome. Rheum Dis Clin North Am 2016; 42 (03) 485-499
  • 71 Kim J, Sun D, Ozl R. , et al. A validated method of labial minor salivary gland biopsy for the diagnosis of Sjögren's syndrome. Laryngoscope 2016; 126 (09) 2041-2046
  • 72 Giovelli RA, Santos MC, Serrano EV, Valim V. Clinical characteristics and biopsy accuracy in suspected cases of Sjögren's syndrome referred to labial salivary gland biopsy. BMC Musculoskelet Disord 2015; 16: 30
  • 73 van Stein-Callenfels D, Tan J, Bloemena E. , et al. The role of a labial salivary gland biopsy in the diagnostic procedure for Sjögren's syndrome; a study of 94 cases. Med Oral Patol Oral Cir Bucal 2014; 19 (04) e372-e376
  • 74 Mossel E, Delli K, van Nimwegen JF. , et al; EULAR US-pSS Study Group. Ultrasonography of major salivary glands compared with parotid and labial gland biopsy and classification criteria in patients with clinically suspected primary Sjögren's syndrome. Ann Rheum Dis 2017; 76 (11) 1883-1889
  • 75 Cornec D, Jousse-Joulin S, Marhadour T. , et al. Salivary gland ultrasonography improves the diagnostic performance of the 2012 American College of Rheumatology classification criteria for Sjögren's syndrome. Rheumatology (Oxford) 2014; 53 (09) 1604-1607
  • 76 Seror R, Ravaud P, Bowman SJ. , et al; EULAR Sjögren's Task Force. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis 2010; 69 (06) 1103-1109
  • 77 Brito-Zerón P, Kostov B, Solans R. , et al; SS Study Group, Autoimmune Diseases Study Group (GEAS), Spanish Society of Internal Medicine (SEMI). Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. Ann Rheum Dis 2016; 75 (02) 348-355
  • 78 Ter Borg EJ, Kelder JC. Development of new extra-glandular manifestations or associated auto-immune diseases after establishing the diagnosis of primary Sjögren's syndrome: a long-term study of the Antonius Nieuwegein Sjögren (ANS) cohort. Rheumatol Int 2017; 37 (07) 1153-1158
  • 79 Ter Borg EJ, Kelder JC. Polyarthritis in primary Sjögren's syndrome represents a distinct subset with less pronounced B cell proliferation a Dutch cohort with long-term follow-up. Clin Rheumatol 2016; 35 (03) 649-655
  • 80 Torrente-Segarra V, Corominas H, Sánchez-Piedra C. , et al; SJOGRENSER Study Group of the Spanish Society of Rheumatology. Fibromyalgia prevalence and associated factors in primary Sjögren's syndrome patients in a large cohort from the Spanish Society of Rheumatology registry (SJOGRENSER). Clin Exp Rheumatol 2017; 35 (03) (Suppl. 105) 28-34
  • 81 Carvajal Alegria G, Guellec D, Devauchelle-Pensec V, Saraux A. Is there specific neurological disorders of primary Sjögren's syndrome?. Joint Bone Spine 2015; 82 (02) 86-89
  • 82 Tobón GJ, Pers JO, Devauchelle-Pensec V, Youinou P. Neurological disorders in primary Sjögren's syndrome. Autoimmune Dis 2012; 2012: 645967
  • 83 Brito-Zerón P, Akasbi M, Bosch X. , et al. Classification and characterisation of peripheral neuropathies in 102 patients with primary Sjögren's syndrome. Clin Exp Rheumatol 2013; 31 (01) 103-110
  • 84 Jamilloux Y, Magy L, Hurtevent JF. , et al. Immunological profiles determine neurological involvement in Sjögren's syndrome. Eur J Intern Med 2014; 25 (02) 177-181
  • 85 Berkowitz AL, Samuels MA. The neurology of Sjogren's syndrome and the rheumatology of peripheral neuropathy and myelitis. Pract Neurol 2014; 14 (01) 14-22
  • 86 Andonopoulos AP, Lagos G, Drosos AA, Moutsopoulos HM. The spectrum of neurological involvement in Sjögren's syndrome. Br J Rheumatol 1990; 29 (01) 21-23
  • 87 Massara A, Bonazza S, Castellino G. , et al. Central nervous system involvement in Sjögren's syndrome: unusual, but not unremarkable--clinical, serological characteristics and outcomes in a large cohort of Italian patients. Rheumatology (Oxford) 2010; 49 (08) 1540-1549
  • 88 Sivadasan A, Muthusamy K, Patel B. , et al. Clinical spectrum, therapeutic outcomes, and prognostic predictors in Sjogren's syndrome-associated neuropathy. Ann Indian Acad Neurol 2017; 20 (03) 278-283
  • 89 Pars K, Pul R, Schwenkenbecher P. , et al. Cerebrospinal fluid findings in neurological diseases associated with Sjögren's syndrome. Eur Neurol 2017; 77 (1-2): 91-102
  • 90 Sène D, Jallouli M, Lefaucheur JP. , et al. Peripheral neuropathies associated with primary Sjögren syndrome: immunologic profiles of nonataxic sensory neuropathy and sensorimotor neuropathy. Medicine (Baltimore) 2011; 90 (02) 133-138
  • 91 Gono T, Kawaguchi Y, Katsumata Y. , et al. Clinical manifestations of neurological involvement in primary Sjögren's syndrome. Clin Rheumatol 2011; 30 (04) 485-490
  • 92 Indart S, Hugon J, Guillausseau PJ. , et al. Impact of pain on cognitive functions in primary Sjögren syndrome with small fiber neuropathy: 10 cases and a literature review. Medicine (Baltimore) 2017; 96 (16) e6384
  • 93 Pereira PR, Viala K, Maisonobe T. , et al. Sjögren sensory neuronopathy (Sjögren ganglionopathy): long-term outcome and treatment response in a series of 13 cases. Medicine (Baltimore) 2016; 95 (19) e3632
  • 94 Mukaino A, Nakane S, Higuchi O. , et al. Insights from the ganglionic acetylcholine receptor autoantibodies in patients with Sjögren's syndrome. Mod Rheumatol 2016; 26 (05) 708-715
  • 95 Mori K, Iijima M, Koike H. , et al. The wide spectrum of clinical manifestations in Sjögren's syndrome-associated neuropathy. Brain 2005; 128 (Pt 11): 2518-2534
  • 96 Scofield RH. Vasculitis in Sjögren's syndrome. Curr Rheumatol Rep 2011; 13 (06) 482-488
  • 97 Kim SM, Waters P, Vincent A. , et al. Sjogren's syndrome myelopathy: spinal cord involvement in Sjogren's syndrome might be a manifestation of neuromyelitis optica. Mult Scler 2009; 15 (09) 1062-1068
  • 98 Zhong YH, Zhong ZG, Zhou Z. , et al. Comparisons of presentations and outcomes of neuromyelitis optica patients with and without Sjögren's syndrome. Neurol Sci 2017; 38 (02) 271-277
  • 99 Yang H, Sun Y, Zhao L, Zhang X, Zhang F. Cerebellar involvement in patients with primary Sjögren's syndrome: diagnosis and treatment. Clin Rheumatol 2018; 37 (05) 1207-1213
  • 100 Delalande S, de Seze J, Fauchais AL. , et al. Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) 2004; 83 (05) 280-291
  • 101 Morreale M, Marchione P, Giacomini P. , et al. Neurological involvement in primary Sjögren syndrome: a focus on central nervous system. PLoS One 2014; 9 (01) e84605
  • 102 Šarac H, Markeljević J, Erdeljić V. , et al. Signal hyperintensities on brain magnetic resonance imaging in patients with primary Sjögren syndrome and frequent episodic tension-type headache: relation to platelet serotonin level and disease activity. J Rheumatol 2013; 40 (08) 1360-1366
  • 103 Owada K, Uchihara T, Ishida K, Mizusawa H, Watabiki S, Tsuchiya K. Motor weakness and cerebellar ataxia in Sjögren syndrome--identification of antineuronal antibody: a case report. J Neurol Sci 2002; 197 (1-2): 79-84
  • 104 Terao Y, Sakai K, Kato S, Tanabe H, Ishida K, Tsukamoto T. Antineuronal antibody in Sjögren's syndrome masquerading as paraneoplastic cerebellar degeneration. Lancet 1994; 343 (8900): 790
  • 105 Niu B, Zou Z, Shen Y, Cao B. A case report of Sjögren syndrome manifesting bilateral basal ganglia lesions. Medicine (Baltimore) 2017; 96 (17) e6715
  • 106 Lalji A, Izbudak I, Birnbaum J. Cortical blindness and not optic neuritis as a cause of vision loss in a Sjögren's syndrome (SS) patient with the neuromyelitis optica spectrum disorder (NMOSD): challenges of ascribing demyelinating syndromes to SS: a case report. Medicine (Baltimore) 2017; 96 (34) e7454
  • 107 Generali E, Costanzo A, Mainetti C, Selmi C. Cutaneous and mucosal manifestations of Sjögren's syndrome. Clin Rev Allergy Immunol 2017; 53 (03) 357-370
  • 108 Kittridge A, Routhouska SB, Korman NJ. Dermatologic manifestations of Sjögren syndrome. J Cutan Med Surg 2011; 15 (01) 8-14
  • 109 Bernacchi E, Amato L, Parodi A. , et al. Sjögren's syndrome: a retrospective review of the cutaneous features of 93 patients by the Italian Group of Immunodermatology. Clin Exp Rheumatol 2004; 22 (01) 55-62
  • 110 Hasegawa J, Hayami N, Hoshino J. , et al. Cryoglobulinemic vasculitis with primary Sjögren’s syndrome: a case report. Mod Rheumatol 2018; 28 (03) 570-574
  • 111 Miyagawa S. Clinical, serological and immunogenetic features of Japanese anti-Ro/SS-A-positive patients with annular erythema. Dermatology 1994; 189 (Suppl. 01) 11-13
  • 112 Brito-Zerón P, Retamozo S, Akasbi M. , et al. Annular erythema in primary Sjogren's syndrome: description of 43 non-Asian cases. Lupus 2014; 23 (02) 166-175
  • 113 Boddu P, Mohammed AS, Khandelwal S. Skin findings in a patient with Sjogren's syndrome. Case Rep Rheumatol 2016; 2016: 4829459
  • 114 Roguedas AM, Misery L, Sassolas B, Le Masson G, Pennec YL, Youinou P. Cutaneous manifestations of primary Sjögren's syndrome are underestimated. Clin Exp Rheumatol 2004; 22 (05) 632-636
  • 115 Goules AV, Tatouli IP, Moutsopoulos HM, Tzioufas AG. Clinically significant renal involvement in primary Sjögren's syndrome: clinical presentation and outcome. Arthritis Rheum 2013; 65 (11) 2945-2953
  • 116 Ram R, Swarnalatha G, Dakshinamurty KV. Renal tubular acidosis in Sjögren's syndrome: a case series. Am J Nephrol 2014; 40 (02) 123-130
  • 117 Evans R, Zdebik A, Ciurtin C, Walsh SB. Renal involvement in primary Sjögren's syndrome. Rheumatology (Oxford) 2015; 54 (09) 1541-1548
  • 118 François H, Mariette X. Renal involvement in primary Sjögren syndrome. Nat Rev Nephrol 2016; 12 (02) 82-93
  • 119 Yang HX, Wang J, Wen YB. , et al. Renal involvement in primary Sjögren’s syndrome: A retrospective study of 103 biopsy-proven cases from a single center in China. Int J Rheum Dis 2018; 21 (01) 223-229
  • 120 Kidder D, Rutherford E, Kipgen D, Fleming S, Geddes C, Stewart GA. Kidney biopsy findings in primary Sjögren syndrome. Nephrol Dial Transplant 2015; 30 (08) 1363-1369
  • 121 Shen Y, Xie J, Lin L. , et al. Combination cyclophosphamide/glucocorticoids provide better tolerability and outcomes versus glucocorticoids alone in patients with Sjogren's associated chronic interstitial nephritis. Am J Nephrol 2017; 46 (06) 473-480
  • 122 Jasiek M, Karras A, Le Guern V. , et al. A multicentre study of 95 biopsy-proven cases of renal disease in primary Sjögren's syndrome. Rheumatology (Oxford) 2017; 56 (03) 362-370
  • 123 Ren H, Wang WM, Chen XN. , et al. Renal involvement and followup of 130 patients with primary Sjögren's syndrome. J Rheumatol 2008; 35 (02) 278-284
  • 124 Yılmaz H, Kaya M, Özbek M, ÜUreten K, Safa Yıldırım İ. Hypokalemic periodic paralysis in Sjogren's syndrome secondary to distal renal tubular acidosis. Rheumatol Int 2013; 33 (07) 1879-1882
  • 125 Maripuri S, Grande JP, Osborn TG. , et al. Renal involvement in primary Sjögren's syndrome: a clinicopathologic study. Clin J Am Soc Nephrol 2009; 4 (09) 1423-1431
  • 126 Kobayashi T, Muto S, Nemoto J. , et al. Fanconi's syndrome and distal (type 1) renal tubular acidosis in a patient with primary Sjögren's syndrome with monoclonal gammopathy of undetermined significance. Clin Nephrol 2006; 65 (06) 427-432
  • 127 Arman F, Shakeri H, Nobakht N, Rastogi A, Kamgar M. A case of kidney involvement in primary Sjögren's syndrome. Am J Case Rep 2017; 18: 622-626
  • 128 Geng Y, Zhao Y, Zhang Z. Tubulointerstitial nephritis-induced hypophosphatemic osteomalacia in Sjögren's syndrome: a case report and review of the literature. Clin Rheumatol 2018; 37 (01) 257-263
  • 129 Saeki T, Nakajima A, Ito T. , et al. Tubulointerstitial nephritis and Fanconi syndrome in a patient with primary Sjögren’s syndrome accompanied by antimitochondrial antibodies: a case report and review of the literature. Mod Rheumatol 2018; 28 (05) 897-900
  • 130 Kim-Lee C, Suresh L, Ambrus Jr JL. Gastrointestinal disease in Sjogren's syndrome: related to food hypersensitivities. Springerplus 2015; 4: 766
  • 131 Volter F, Fain O, Mathieu E, Thomas M. Esophageal function and Sjögren's syndrome. Dig Dis Sci 2004; 49 (02) 248-253
  • 132 Türk T, Pirildar T, Tunç E, Bor S, Doğanavşargil E. Manometric assessment of esophageal motility in patients with primary Sjögren's syndrome. Rheumatol Int 2005; 25 (04) 246-249
  • 133 Hammar O, Ohlsson B, Wollmer P, Mandl T. Impaired gastric emptying in primary Sjogren's syndrome. J Rheumatol 2010; 37 (11) 2313-2318
  • 134 Chang CS, Liao CH, Muo CH, Kao CH. Increased risk of concurrent gastroesophageal reflux disease among patients with Sjögren's syndrome: a nationwide population-based study. Eur J Intern Med 2016; 31: 73-78
  • 135 Liao CY, Chien ST, Wang CC. , et al. Sjögren's syndrome associated with protein losing gastroenteropathy manifested by intestinal lymphangiectasia successfully treated with prednisolone and hydroxychloroquine. Lupus 2015; 24 (14) 1552-1556
  • 136 Ebert EC. Gastrointestinal and hepatic manifestations of Sjogren syndrome. J Clin Gastroenterol 2012; 46 (01) 25-30
  • 137 Lee SW, Kim BK, Park JY. , et al. Clinical predictors of silent but substantial liver fibrosis in primary Sjogren's syndrome. Mod Rheumatol 2016; 26 (04) 576-582
  • 138 Skopouli FN, Barbatis C, Moutsopoulos HM. Liver involvement in primary Sjögren's syndrome. Br J Rheumatol 1994; 33 (08) 745-748
  • 139 Okubo H, Maekawa H, Ogawa K. , et al. Pseudolymphoma of the liver associated with Sjögren's syndrome. Scand J Rheumatol 2001; 30 (02) 117-119
  • 140 Mandl T, Marsal J, Olsson P, Ohlsson B, Andréasson K. Severe intestinal dysbiosis is prevalent in primary Sjögren's syndrome and is associated with systemic disease activity. Arthritis Res Ther 2017; 19 (01) 237
  • 141 Forbes JD, Van Domselaar G, Bernstein CN. The gut microbiota in immune-mediated inflammatory diseases. Front Microbiol 2016; 7: 1081
  • 142 de Paiva CS, Jones DB, Stern ME. , et al. Altered mucosal microbiome diversity and disease severity in Sjögren syndrome. Sci Rep 2016; 6: 23561
  • 143 Chen CT, Tseng YC, Yang CW. , et al. Increased risks of spontaneous bacterial peritonitis and interstitial lung disease in primary biliary cirrhosis patients with concomitant Sjögren syndrome. Medicine (Baltimore) 2016; 95 (02) e2537
  • 144 Schattner A, Friedman J, Klepfish A, Berrebi A. Immune cytopenias as the presenting finding in primary Sjögren's syndrome. QJM 2000; 93 (12) 825-829
  • 145 Qiao L, Chen J, Leng XM. , et al. Agranulocytosis and mixed-type autoimmune hemolytic anemia in primary Sjögren's syndrome: a case report and review of the literature. Int J Rheum Dis 2016; 19 (12) 1351-1353
  • 146 Rizzi R, Pastore D, Liso A. , et al. Autoimmune myelofibrosis: report of three cases and review of the literature. Leuk Lymphoma 2004; 45 (03) 561-566
  • 147 Wen W, Liu Y, Zhao C, Sun X, Zhang C, Li Z. Clinical and serologic features of primary Sjögren's syndrome concomitant with autoimmune hemolytic anemia: a large-scale cross-sectional study. Clin Rheumatol 2015; 34 (11) 1877-1884
  • 148 Lin TY, Chang CC, Chang CC, Yuan JY, Chen HH. Cyclophosphamide-rescued plasmapheresis-unresponsive secondary thrombotic thrombocytopenic purpura caused by Sjögren's syndrome. Arch Med Sci 2012; 8 (05) 934-938
  • 149 Fukaya S, Yasuda S, Hashimoto T. , et al. Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases. Rheumatology (Oxford) 2008; 47 (11) 1686-1691
  • 150 Brito-Zerón P, Retamozo S, Gandía M. , et al. Monoclonal gammopathy related to Sjögren syndrome: a key marker of disease prognosis and outcomes. J Autoimmun 2012; 39 (1-2): 43-48
  • 151 Voulgarelis M, Moutsopoulos HM. Mucosa-associated lymphoid tissue lymphoma in Sjögren's syndrome: risks, management, and prognosis. Rheum Dis Clin North Am 2008; 34 (04) 921-933 , viii
  • 152 Nocturne G, Virone A, Ng WF. , et al. Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjögren's syndrome. Arthritis Rheumatol 2016; 68 (04) 977-985
  • 153 Upala S, Yong WC, Sanguankeo A. Association between primary Sjögren's syndrome and pregnancy complications: a systematic review and meta-analysis. Clin Rheumatol 2016; 35 (08) 1949-1955
  • 154 De Carolis S, Salvi S, Botta A. , et al. The impact of primary Sjogren's syndrome on pregnancy outcome: our series and review of the literature. Autoimmun Rev 2014; 13 (02) 103-107
  • 155 Ballester C, Grobost V, Roblot P. , et al. Pregnancy and primary Sjögren's syndrome: management and outcomes in a multicentre retrospective study of 54 pregnancies. Scand J Rheumatol 2017; 46 (01) 56-63
  • 156 Skog A, Lagnefeldt L, Conner P, Wahren-Herlenius M, Sonesson SE. Outcome in 212 anti-Ro/SSA-positive pregnancies and population-based incidence of congenital heart block. Acta Obstet Gynecol Scand 2016; 95 (01) 98-105
  • 157 Doti PI, Escoda O, Cesar-Díaz S. , et al. Congenital heart block related to maternal autoantibodies: descriptive analysis of a series of 18 cases from a single center. Clin Rheumatol 2016; 35 (02) 351-356
  • 158 Rischmueller M, Tieu J, Lester S. Primary Sjögren's syndrome. Best Pract Res Clin Rheumatol 2016; 30 (01) 189-220
  • 159 Skog A, Wahren-Herlenius M, Sundström B, Bremme K, Sonesson SE. Outcome and growth of infants fetally exposed to heart block-associated maternal anti-Ro52/SSA autoantibodies. Pediatrics 2008; 121 (04) e803-e809
  • 160 Valim V, Gerdts E, Jonsson R. , et al. Atherosclerosis in Sjögren's syndrome: evidence, possible mechanisms and knowledge gaps. Clin Exp Rheumatol 2016; 34 (01) 133-142
  • 161 Liang M, Bao L, Xiong N. , et al. Cardiac arrhythmias as the initial manifestation of adult primary Sjögren's syndrome: a case report and literature review. Int J Rheum Dis 2015; 18 (07) 800-806
  • 162 Brito-Zerón P, Izmirly PM, Ramos-Casals M, Buyon JP, Khamashta MA. The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol 2015; 11 (05) 301-312
  • 163 Vassiliou VA, Moyssakis I, Boki KA, Moutsopoulos HM. Is the heart affected in primary Sjögren's syndrome? An echocardiographic study. Clin Exp Rheumatol 2008; 26 (01) 109-112
  • 164 Parambil JG, Myers JL, Lindell RM, Matteson EL, Ryu JH. Interstitial lung disease in primary Sjögren syndrome. Chest 2006; 130 (05) 1489-1495
  • 165 Papageorgiou A, Voulgarelis M, Tzioufas AG. Clinical picture, outcome and predictive factors of lymphoma in Sjögren syndrome. Autoimmun Rev 2015; 14 (07) 641-649
  • 166 Liang Y, Yang Z, Qin B, Zhong R. Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis 2014; 73 (06) 1151-1156
  • 167 Routsias JG, Goules JD, Charalampakis G, Tzima S, Papageorgiou A, Voulgarelis M. Malignant lymphoma in primary Sjögren's syndrome: an update on the pathogenesis and treatment. Semin Arthritis Rheum 2013; 43 (02) 178-186
  • 168 Chiu YH, Chung CH, Lin KT. , et al. Predictable biomarkers of developing lymphoma in patients with Sjögren syndrome: a nationwide population-based cohort study. Oncotarget 2017; 8 (30) 50098-50108
  • 169 Vasaitis L, Nordmark G, Theander E. , et al. Comparison of patients with and without pre-existing lymphoma at diagnosis of primary Sjögren's syndrome. Scand J Rheumatol 2018; 1-6 . doi: 10.1080/03009742.2018.1523456
  • 170 Titsinides S, Nikitakis N, Piperi E, Sklavounou A. MALT lymphoma of minor salivary glands in a Sjögren's syndrome patient: a case report and review of literature. J Oral Maxillofac Res 2017; 8 (01) e5
  • 171 Movahed R, Weiss A, Velez I, Dym H. Submandibular gland MALT lymphoma associated with Sjögren's syndrome: case report. J Oral Maxillofac Surg 2011; 69 (11) 2924-2929
  • 172 Yachoui R, Leon C, Sitwala K, Kreidy M. Pulmonary MALT lymphoma in patients with Sjögren's syndrome. Clin Med Res 2017; 15 (1-2): 6-12
  • 173 Borie R, Wislez M, Thabut G. , et al. Clinical characteristics and prognostic factors of pulmonary MALT lymphoma. Eur Respir J 2009; 34 (06) 1408-1416
  • 174 Cui L, Elzakra N, Xu S, Xiao GG, Yang Y, Hu S. Investigation of three potential autoantibodies in Sjogren's syndrome and associated MALT lymphoma. Oncotarget 2017; 8 (18) 30039-30049
  • 175 Manzo C, Kechida M. Is primary Sjögren's syndrome a risk factor for malignancies different from lymphomas? What does the literature highlight about it?. Reumatologia 2017; 55 (03) 136-139
  • 176 Hernandez-Molina G, Faz-Munoz D, Astudillo-Angel M, Iturralde-Chavez A, Reyes E. Coexistence of amyloidosis and primary Sjogren's syndrome: an overview. Curr Rheumatol Rev 2018; 14 (03) 231-238
  • 177 Mazori DR, Femia AN. Primary cutaneous nodular amyloidosis in association with Sjögren's syndrome. Joint Bone Spine 2016; 83 (03) 350
  • 178 Egashira R, Kondo T, Hirai T. , et al. CT findings of thoracic manifestations of primary Sjögren syndrome: radiologic-pathologic correlation. Radiographics 2013; 33 (07) 1933-1949
  • 179 Gutsche M, Rosen GD, Swigris JJ. Connective tissue disease-associated interstitial lung disease: a review. Curr Respir Care Rep 2012; 1: 224-232
  • 180 Reuss-Borst MA, Hartmann U. Pulmonary nodules as initial manifestation of primary Sjogren's syndrome. Ann Rheum Dis 2006; 65 (05) 685-687
  • 181 Panchabhai TS, Farver C, Highland KB. Lymphocytic interstitial pneumonia. Clin Chest Med 2016; 37 (03) 463-474
  • 182 Fairfax AJ, Haslam PL, Pavia D. , et al. Pulmonary disorders associated with Sjögren's syndrome. Q J Med 1981; 50 (199) 279-295
  • 183 Kampolis CF, Fragkioudaki S, Mavragani CP, Zormpala A, Samakovli A, Moutsopoulos HM. Prevalence and spectrum of symptomatic pulmonary involvement in primary Sjögren's syndrome. Clin Exp Rheumatol 2018; 36 (03) (Suppl. 112) 94-101
  • 184 Strevens Bolmgren V, Olsson P, Wollmer P, Hesselstrand R, Mandl T. Respiratory symptoms are poor predictors of concomitant chronic obstructive pulmonary disease in patients with primary Sjögren's syndrome. Rheumatol Int 2017; 37 (05) 813-818
  • 185 Papiris SA, Saetta M, Turato G. , et al. CD4-positive T-lymphocytes infiltrate the bronchial mucosa of patients with Sjögren's syndrome. Am J Respir Crit Care Med 1997; 156 (2, Pt 1): 637-641
  • 186 Gudbjörnsson B, Hedenström H, Stålenheim G, Hällgren R. Bronchial hyperresponsiveness to methacholine in patients with primary Sjögren's syndrome. Ann Rheum Dis 1991; 50 (01) 36-40
  • 187 Stålenheim G, Gudbjörnsson B. Anti-inflammatory drugs do not alleviate bronchial hyperreactivity in Sjögren's syndrome. Allergy 1997; 52 (04) 423-427
  • 188 Shen TC, Chen HJ, Wei CC. , et al. Risk of asthma in patients with primary Sjögren's syndrome: a retrospective cohort study. BMC Pulm Med 2016; 16 (01) 152
  • 189 Shen TC, Wu BR, Chen HJ. , et al. Risk of chronic obstructive pulmonary disease in female adults with primary Sjögren syndrome: a nationwide population-based cohort study. Medicine (Baltimore) 2016; 95 (10) e3066
  • 190 Nilsson AM, Diaz S, Theander E. , et al. Chronic obstructive pulmonary disease is common in never-smoking patients with primary Sjögren syndrome. J Rheumatol 2015; 42 (03) 464-471
  • 191 Ito I, Nagai S, Kitaichi M. , et al. Pulmonary manifestations of primary Sjogren's syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med 2005; 171 (06) 632-638
  • 192 Ryu JH, Myers JL, Swensen SJ. Bronchiolar disorders. Am J Respir Crit Care Med 2003; 168 (11) 1277-1292
  • 193 Yousem SA, Colby TV, Carrington CB. Follicular bronchitis/bronchiolitis. Hum Pathol 1985; 16 (07) 700-706
  • 194 Aerni MR, Vassallo R, Myers JL, Lindell RM, Ryu JH. Follicular bronchiolitis in surgical lung biopsies: clinical implications in 12 patients. Respir Med 2008; 102 (02) 307-312
  • 195 Travis WD, Galvin JR. Non-neoplastic pulmonary lymphoid lesions. Thorax 2001; 56 (12) 964-971
  • 196 Shi JH, Liu HR, Xu WB. , et al. Pulmonary manifestations of Sjögren's syndrome. Respiration 2009; 78 (04) 377-386
  • 197 Nakanishi M, Fukuoka J, Tanaka T. , et al. Small airway disease associated with Sjögren's syndrome: clinico-pathological correlations. Respir Med 2011; 105 (12) 1931-1938
  • 198 Roca F, Dominique S, Schmidt J. , et al. Interstitial lung disease in primary Sjögren's syndrome. Autoimmun Rev 2017; 16 (01) 48-54
  • 199 Atzeni F, Gerardi MC, Barilaro G, Masala IF, Benucci M, Sarzi-Puttini P. Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review. Expert Rev Clin Immunol 2018; 14 (01) 69-82
  • 200 Palm O, Garen T, Berge Enger T. , et al. Clinical pulmonary involvement in primary Sjogren's syndrome: prevalence, quality of life and mortality--a retrospective study based on registry data. Rheumatology (Oxford) 2013; 52 (01) 173-179
  • 201 Manfredi A, Sebastiani M, Cerri S. , et al. Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement. Clin Rheumatol 2017; 36 (06) 1261-1268
  • 202 Gao H, Zhang XW, He J. , et al. Prevalence, risk factors, and prognosis of interstitial lung disease in a large cohort of Chinese primary Sjögren syndrome patients: a case-control study. Medicine (Baltimore) 2018; 97 (24) e11003
  • 203 Yazisiz V, Arslan G, Ozbudak IH. , et al. Lung involvement in patients with primary Sjögren's syndrome: what are the predictors?. Rheumatol Int 2010; 30 (10) 1317-1324
  • 204 Uffmann M, Kiener HP, Bankier AA, Baldt MM, Zontsich T, Herold CJ. Lung manifestation in asymptomatic patients with primary Sjögren syndrome: assessment with high resolution CT and pulmonary function tests. J Thorac Imaging 2001; 16 (04) 282-289
  • 205 Wang Y, Hou Z, Qiu M, Ye Q. Risk factors for primary Sjögren syndrome-associated interstitial lung disease. J Thorac Dis 2018; 10 (04) 2108-2117
  • 206 Enomoto Y, Takemura T, Hagiwara E. , et al. Prognostic factors in interstitial lung disease associated with primary Sjögren's syndrome: a retrospective analysis of 33 pathologically-proven cases. PLoS One 2013; 8 (09) e73774
  • 207 Reina D, Roig Vilaseca D, Torrente-Segarra V. , et al. Sjögren's syndrome-associated interstitial lung disease: a multicenter study. Reumatol Clin 2016; 12 (04) 201-205
  • 208 Kashif M, Arya D, Niazi M, Khaja M. A rare case of necrotizing myopathy and fibrinous and organizing pneumonia with anti-EJ antisynthetase syndrome and SSA antibodies. Am J Case Rep 2017; 18: 448-453
  • 209 Kokosi M, Riemer EC, Highland KB. Pulmonary involvement in Sjögren syndrome. Clin Chest Med 2010; 31 (03) 489-500
  • 210 Enomoto Y, Nakamura Y, Colby TV. , et al. Radiologic pleuroparenchymal fibroelastosis-like lesion in connective tissue disease-related interstitial lung disease. PLoS One 2017; 12 (06) e0180283
  • 211 Davidson BK, Kelly CA, Griffiths ID. Ten year follow up of pulmonary function in patients with primary Sjögren's syndrome. Ann Rheum Dis 2000; 59 (09) 709-712
  • 212 Worthy SA, Flint JD, Müller NL. Pulmonary complications after bone marrow transplantation: high-resolution CT and pathologic findings. Radiographics 1997; 17 (06) 1359-1371
  • 213 Müller NL, Staples CA, Miller RR. Bronchiolitis obliterans organizing pneumonia: CT features in 14 patients. AJR Am J Roentgenol 1990; 154 (05) 983-987
  • 214 Feinstein MB, DeSouza SA, Moreira AL. , et al. A comparison of the pathological, clinical and radiographical, features of cryptogenic organising pneumonia, acute fibrinous and organising pneumonia and granulomatous organising pneumonia. J Clin Pathol 2015; 68 (06) 441-447
  • 215 Lazor R, Vandevenne A, Pelletier A, Leclerc P, Court-Fortune I, Cordier JF. Cryptogenic organizing pneumonia. Characteristics of relapses in a series of 48 patients. The Groupe d'Etudes et de Recherche sur les Maladles “Orphelines” Pulmonaires (GERM“O”P). Am J Respir Crit Care Med 2000; 162 (2, Pt 1): 571-577
  • 216 Berkowitz EA, Henry TS, Veeraraghavan S, Staton Jr GW, Gal AA. Pulmonary effects of synthetic marijuana: chest radiography and CT findings. AJR Am J Roentgenol 2015; 204 (04) 750-757
  • 217 Dong X, Zheng Y, Wang L, Chen WH, Zhang YG, Fu Q. Clinical characteristics of autoimmune rheumatic disease-related organizing pneumonia. Clin Rheumatol 2018; 37 (04) 1027-1035
  • 218 Lynch DA. Lung disease related to collagen vascular disease. J Thorac Imaging 2009; 24 (04) 299-309
  • 219 Cordier JF, Cottin V, Lazor R, Thivolet-Béjui F. Many faces of bronchiolitis and organizing pneumonia. Semin Respir Crit Care Med 2016; 37 (03) 421-440
  • 220 Baque-Juston M, Pellegrin A, Leroy S, Marquette CH, Padovani B. Organizing pneumonia: What is it? A conceptual approach and pictorial review. Diagn Interv Imaging 2014; 95 (09) 771-777
  • 221 Bouchardy LM, Kuhlman JE, Ball Jr WC, Hruban RH, Askin FB, Siegelman SS. CT findings in bronchiolitis obliterans organizing pneumonia (BOOP) with radiographic, clinical, and histologic correlation. J Comput Assist Tomogr 1993; 17 (03) 352-357
  • 222 Matteson EL, Ike RW. Bronchiolitis obliterans organizing pneumonia and Sjögren's syndrome. J Rheumatol 1990; 17 (05) 676-679
  • 223 Usui Y, Kimula Y, Miura H. , et al. A case of bronchiolitis obliterans organizing pneumonia associated with primary Sjögren's syndrome who died of superimposed diffuse alveolar damage. Respiration 1992; 59 (02) 122-124
  • 224 Lambert M, Hebbar M, Viget N, Hatron PY, Hachulla E, Devulder B. [Bronchiolitis obliterans with organized pneumonia: a rare complication of primary Gougerot-Sjögren syndrome]. Rev Med Interne 2000; 21 (01) 74-77
  • 225 Ioannou S, Toya SP, Tomos P, Tzelepis GE. Cryptogenic organizing pneumonia associated with primary Sjogren's syndrome. Rheumatol Int 2008; 28 (10) 1053-1055
  • 226 Justet A, Ottaviani S, Dieudé P, Taillé C. Tocilizumab for refractory organising pneumonia associated with Sjögren's disease. BMJ Case Rep 2015; 2015: 201
  • 227 Beasley MB, Franks TJ, Galvin JR, Gochuico B, Travis WD. Acute fibrinous and organizing pneumonia: a histological pattern of lung injury and possible variant of diffuse alveolar damage. Arch Pathol Lab Med 2002; 126 (09) 1064-1070
  • 228 Khan A, Humayun M, Haider I, Ayub M, Shah Z, Ajmal F. Primary Sjogren's syndrome presenting as acute interstitial pneumonitis/Hamman-Rich syndrome. Case Rep Med 2016; 2016: 4136765
  • 229 Lin Y, Yi Q, Cheng D. Rapid progressive interstitial lung disease as initial manifestation of primary Sjögren's syndrome: a case report. Int J Clin Exp Med 2014; 7 (12) 5904-5908
  • 230 Vourlekis JS, Brown KK, Cool CD. , et al. Acute interstitial pneumonitis. Case series and review of the literature. Medicine (Baltimore) 2000; 79 (06) 369-378
  • 231 Collard HR, Ryerson CJ, Corte TJ. , et al. Acute exacerbation of idiopathic pulmonary fibrosis. An International Working Group Report. Am J Respir Crit Care Med 2016; 194 (03) 265-275
  • 232 Ye S, Chen XX, Lu XY. , et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol 2007; 26 (10) 1647-1654
  • 233 Tachikawa R, Tomii K, Ueda H. , et al. Clinical features and outcome of acute exacerbation of interstitial pneumonia: collagen vascular diseases-related versus idiopathic. Respiration 2012; 83 (01) 20-27
  • 234 Parambil JG, Myers JL, Ryu JH. Diffuse alveolar damage: uncommon manifestation of pulmonary involvement in patients with connective tissue diseases. Chest 2006; 130 (02) 553-558
  • 235 Toyoda Y, Hanibuchi M, Kishi J. , et al. Clinical features and outcome of acute exacerbation of interstitial pneumonia associated with connective tissue disease. J Med Invest 2016; 63 (3-4): 294-299
  • 236 Xu KF, Feng R, Cui H. , et al. Diffuse cystic lung diseases: diagnostic considerations. Semin Respir Crit Care Med 2016; 37 (03) 457-467
  • 237 Henriet AC, Diot E, Marchand-Adam S. , et al. Organising pneumonia can be the inaugural manifestation in connective tissue diseases, including Sjogren's syndrome. Eur Respir Rev 2010; 19 (116) 161-163
  • 238 Fasanya A, Gandhi V, DiCarlo C, Thirumala R. Acute fibrinous and organizing pneumonia in a patient with Sjogren's syndrome. Respir Med Case Rep 2016; 20: 28-30
  • 239 Wang Y, Zhao S, Du G. , et al. Acute fibrinous and organizing pneumonia as initial presentation of primary Sjögren's syndrome: a case report and literature review. Clin Rheumatol 2018; 37 (07) 2001-2005
  • 240 Rapaka V, Hussain MA, Niazi M, Diaz-Fuentes G. Severe acute fibrinous and organizing pneumonia causing acute respiratory distress syndrome and shock. J Bronchology Interv Pulmonol 2011; 18 (03) 269-273
  • 241 Gomes R, Padrão E, Dabó H. , et al. Acute fibrinous and organizing pneumonia: a report of 13 cases in a tertiary university hospital. Medicine (Baltimore) 2016; 95 (27) e4073
  • 242 Hariri LP, Unizony S, Stone J. , et al. Acute fibrinous and organizing pneumonia in systemic lupus erythematosus: a case report and review of the literature. Pathol Int 2010; 60 (11) 755-759
  • 243 Valim V, Rocha RH, Couto RB, Paixão TS, Serrano EV. Acute fibrinous and organizing pneumonia and undifferentiated connective tissue disease: a case report. Case Rep Rheumatol 2012; 2012: 549298
  • 244 Prahalad S, Bohnsack JF, Maloney CG, Leslie KO. Fatal acute fibrinous and organizing pneumonia in a child with juvenile dermatomyositis. J Pediatr 2005; 146 (02) 289-292
  • 245 Koyama M, Johkoh T, Honda O. , et al. Chronic cystic lung disease: diagnostic accuracy of high-resolution CT in 92 patients. AJR Am J Roentgenol 2003; 180 (03) 827-835
  • 246 Srivali N, Ungprasert P, Cheungpasitporn W, Thongprayoon C, Caples SM. Lung cavities in Sjögren's syndrome. QJM 2016; 109 (02) 135-136
  • 247 Gupta N, Wikenheiser-Brokamp KA, Fischer A, McCormack FX. Diffuse cystic lung disease as the presenting manifestation of Sjögren syndrome. Ann Am Thorac Soc 2016; 13 (03) 371-375
  • 248 Takahashi H, Tsuboi H, Yokosawa M. , et al. Diffusion-weighted magnetic resonance imaging of parotid glands before and after abatacept therapy in patients with Sjögren's syndrome associated with rheumatoid arthritis: utility to evaluate and predict response to treatment. Mod Rheumatol 2018; 28 (02) 300-307
  • 249 Lee G, Lee HY, Lee KS. , et al. Imaging manifestations of autoimmune disease-associated lymphoproliferative disorders of the lung. Clin Rheumatol 2013; 32 (10) 1459-1465
  • 250 Swigris JJ, Berry GJ, Raffin TA, Kuschner WG. Lymphoid interstitial pneumonia: a narrative review. Chest 2002; 122 (06) 2150-2164
  • 251 Taouli B, Brauner MW, Mourey I, Lemouchi D, Grenier PA. Thin-section chest CT findings of primary Sjögren's syndrome: correlation with pulmonary function. Eur Radiol 2002; 12 (06) 1504-1511
  • 252 Sverzellati N, Lynch DA, Hansell DM, Johkoh T, King Jr TE, Travis WD. American Thoracic Society-European Respiratory Society Classification of the idiopathic interstitial pneumonias: advances in knowledge since 2002. Radiographics 2015; 35 (07) 1849-1871
  • 253 Bae YA, Lee KS, Han J. , et al. Marginal zone B-cell lymphoma of bronchus-associated lymphoid tissue: imaging findings in 21 patients. Chest 2008; 133 (02) 433-440
  • 254 Li P, Cheung L, Chiu B. Early bronchus-associated lymphoid tissue lymphoma diagnosed with immunoglobulin heavy chain molecular testing. Can Respir J 2016; 2016: 7056035
  • 255 Makimoto G, Asano M, Fujimoto N. , et al. Bilateral pleural effusions as an initial presentation in primary Sjögren's syndrome. Case Rep Rheumatol 2012; 2012: 640353
  • 256 Teshigawara K, Kakizaki S, Horiya M. , et al. Primary Sjogren's syndrome complicated by bilateral pleural effusion. Respirology 2008; 13 (01) 155-158
  • 257 Ma D, Lu H, Qu Y, Wang S, Ying Y, Xiao W. Primary Sjögren's syndrome accompanied by pleural effusion: a case report and literature review. Int J Clin Exp Pathol 2015; 8 (11) 15322-15327
  • 258 Ferreiro L, San José E, Suárez-Antelo J, Valdés L. Primary Sjögren syndrome with pleural effusion. Arch Bronconeumol 2017; 53 (10) 598-600
  • 259 Hosoda C, Hosaka Y, Ryu K, Kinoshita A, Saito K, Kuwano K. Pleuritis associated with primary Sjogren syndrome. Respirol Case Rep 2017; 6 (02) e00285
  • 260 Oda T, Ogura T, Kitamura H. , et al. Distinct characteristics of pleuroparenchymal fibroelastosis with usual interstitial pneumonia compared with idiopathic pulmonary fibrosis. Chest 2014; 146 (05) 1248-1255
  • 261 Cheng SK, Chuah KL. Pleuroparenchymal fibroelastosis of the lung: a review. Arch Pathol Lab Med 2016; 140 (08) 849-853
  • 262 Rosenbaum JN, Butt YM, Johnson KA. , et al. Pleuroparenchymal fibroelastosis: a pattern of chronic lung injury. Hum Pathol 2015; 46 (01) 137-146
  • 263 Reddy TL, Tominaga M, Hansell DM. , et al. Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes. Eur Respir J 2012; 40 (02) 377-385
  • 264 Beynat-Mouterde C, Beltramo G, Lezmi G. , et al. Pleuroparenchymal fibroelastosis as a late complication of chemotherapy agents. Eur Respir J 2014; 44 (02) 523-527
  • 265 Volkmann ER, Chung A, Saggar R, Belperio JA, Lynch III JP. Pulmonary hypertension complicating connective tissue disease. Semin Respir Crit Care Med 2017; 38 (05) 619-635
  • 266 Launay D, Hachulla E, Hatron PY, Jais X, Simonneau G, Humbert M. Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome: report of 9 new cases and review of the literature. Medicine (Baltimore) 2007; 86 (05) 299-315
  • 267 Liu Z, Yang X, Tian Z. , et al. The prognosis of pulmonary arterial hypertension associated with primary Sjögren's syndrome: a cohort study. Lupus 2018; 27 (07) 1072-1080
  • 268 Zhao J, Wang Q, Liu Y. , et al. Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: a cohort study in China. Int J Cardiol 2017; 236: 432-437
  • 269 Condliffe R, Kiely DG, Peacock AJ. , et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179 (02) 151-157
  • 270 Yasuoka H, Shirai Y, Tamura Y, Takeuchi T, Kuwana M. Predictors of favorable responses to immunosuppressive treatment in pulmonary arterial hypertension associated with connective tissue disease. Circ J 2018; 82 (02) 546-554
  • 271 Gaine S, Chin K, Coghlan G. , et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J 2017; 50 (02) 1602493
  • 272 Humbert M, Coghlan JG, Ghofrani HA. , et al. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis 2017; 76 (02) 422-426
  • 273 Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006; 65 (10) 1336-1340
  • 274 Kanwar M, Raina A, Passineau M, Benza R. Idiopathic pulmonary arterial hypertension: evolving therapeutic strategies. Semin Respir Crit Care Med 2017; 38 (05) 606-618
  • 275 Sitbon O, Channick R, Chin KM. , et al; GRIPHON Investigators. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015; 373 (26) 2522-2533
  • 276 Barst RJ, Rubin LJ, Long WA. , et al; Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334 (05) 296-301
  • 277 Rubin LJ, Badesch DB, Barst RJ. , et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346 (12) 896-903
  • 278 Galiè N, Barberà JA, Frost AE. , et al; AMBITION Investigators. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373 (09) 834-844
  • 279 Oudiz RJ, Schilz RJ, Barst RJ. , et al; Treprostinil Study Group. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004; 126 (02) 420-427
  • 280 Coghlan JG, Galiè N, Barberà JA. , et al; AMBITION Investigators. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis 2017; 76 (07) 1219-1227
  • 281 Milani P, Basset M, Russo F, Foli A, Palladini G, Merlini G. The lung in amyloidosis. Eur Respir Rev 2017; 26 (145) 26
  • 282 Rajagopala S, Singh N, Gupta K, Gupta D. Pulmonary amyloidosis in Sjogren's syndrome: a case report and systematic review of the literature. Respirology 2010; 15 (05) 860-866
  • 283 Jeong YJ, Lee KS, Chung MP. , et al. Amyloidosis and lymphoproliferative disease in Sjögren syndrome: thin-section computed tomography findings and histopathologic comparisons. J Comput Assist Tomogr 2004; 28 (06) 776-781
  • 284 Baqir M, Kluka EM, Aubry MC. , et al. Amyloid-associated cystic lung disease in primary Sjögren's syndrome. Respir Med 2013; 107 (04) 616-621
  • 285 Nakamura N, Yamada G, Itoh T. , et al. Pulmonary MALT lymphoma with amyloid production in a patient with primary Sjögren's syndrome. Intern Med 2002; 41 (04) 309-311
  • 286 Khoor A, Colby TV. Amyloidosis of the Lung. Arch Pathol Lab Med 2017; 141 (02) 247-254
  • 287 Aviña-Zubieta JA, Jansz M, Sayre EC, Choi HK. The risk of deep venous thrombosis and pulmonary embolism in primary Sjögren Syndrome: a general population-based study. J Rheumatol 2017; 44 (08) 1184-1189
  • 288 Chung WS, Lin CL, Sung FC, Hsu WH, Chen YF, Kao CH. Increased risks of deep vein thrombosis and pulmonary embolism in Sjögren syndrome: a nationwide cohort study. J Rheumatol 2014; 41 (05) 909-915
  • 289 Barone F, Colafrancesco S. Sjögren's syndrome: from pathogenesis to novel therapeutic targets. Clin Exp Rheumatol 2016; 34 (04) (Suppl. 98) 58-62
  • 290 Lamblin C, Bergoin C, Saelens T, Wallaert B. Interstitial lung diseases in collagen vascular diseases. Eur Respir J Suppl 2001; 32: 69s-80s
  • 291 Gheitasi H, Kostov B, Solans R. , et al; SS Study Group, Autoimmune Diseases Study Group (GEAS), Spanish Society of Internal Medicine (SEMI). How are we treating our systemic patients with primary Sjögren syndrome? Analysis of 1120 patients. Int Immunopharmacol 2015; 27 (02) 194-199
  • 292 Demarchi J, Papasidero S, Medina MA. , et al. Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy. Clin Rheumatol 2017; 36 (11) 2455-2460
  • 293 Wang SQ, Zhang LW, Wei P, Hua H. Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis. BMC Musculoskelet Disord 2017; 18 (01) 186
  • 294 Fox RI, Fox CM. Sjögren syndrome: Why do clinical trials fail?. Rheum Dis Clin North Am 2016; 42 (03) 519-530
  • 295 Barnes H, Holland AE, Westall GP, Goh NS, Glaspole IN. Cyclophosphamide for connective tissue disease-associated interstitial lung disease. Cochrane Database Syst Rev 2018; 1: CD010908
  • 296 Lynch III JP, McCune WJ. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med 1997; 155 (02) 395-420
  • 297 Akpek EK, Lindsley KB, Adyanthaya RS, Swamy R, Baer AN, McDonnell PJ. Treatment of Sjögren's syndrome-associated dry eye an evidence-based review. Ophthalmology 2011; 118 (07) 1242-1252
  • 298 Yoon CH, Lee HJ, Lee EY. , et al. Effect of hydroxychloroquine treatment on dry eyes in subjects with primary Sjögren's syndrome: a double-blind randomized control study. J Korean Med Sci 2016; 31 (07) 1127-1135
  • 299 Ramos-Casals M, Tzioufas AG, Stone JH, Sisó A, Bosch X. Treatment of primary Sjögren syndrome: a systematic review. JAMA 2010; 304 (04) 452-460
  • 300 Tashkin DP, Elashoff R, Clements PJ. , et al; Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354 (25) 2655-2666
  • 301 Tashkin DP, Roth MD, Clements PJ. , et al; Sclerodema Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016; 4 (09) 708-719
  • 302 Volkmann ER, Tashkin DP, Li N. , et al. Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of Scleroderma Lung Studies I and II. Arthritis Rheumatol 2017; 69 (07) 1451-1460
  • 303 Poormoghim H, Moradi Lakeh M, Mohammadipour M, Sodagari F, Toofaninjed N. Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis. Rheumatol Int 2012; 32 (08) 2431-2444
  • 304 Deheinzelin D, Capelozzi VL, Kairalla RA, Barbas Filho JV, Saldiva PH, de Carvalho CR. Interstitial lung disease in primary Sjögren's syndrome. Clinical-pathological evaluation and response to treatment. Am J Respir Crit Care Med 1996; 154 (3, Pt 1): 794-799
  • 305 Carubbi F, Alunno A, Cipriani P. , et al. Rituximab in primary Sjögren's syndrome: a ten-year journey. Lupus 2014; 23 (13) 1337-1349
  • 306 Schioppo T, Ingegnoli F. Current perspective on rituximab in rheumatic diseases. Drug Des Devel Ther 2017; 11: 2891-2904
  • 307 Gottenberg JE, Cinquetti G, Larroche C. , et al; Club Rhumatismes et Inflammations and the French Society of Rheumatology. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis 2013; 72 (06) 1026-1031
  • 308 Devauchelle-Pensec V, Mariette X, Jousse-Joulin S. , et al. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med 2014; 160 (04) 233-242
  • 309 Seror R, Sordet C, Guillevin L. , et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis 2007; 66 (03) 351-357
  • 310 Fisher BA, Everett CC, Rout J. , et al. Effect of rituximab on a salivary gland ultrasound score in primary Sjögren’s syndrome: results of the TRACTISS randomised double-blind multicentre substudy. Ann Rheum Dis 2018; 77 (03) 412-416
  • 311 Mariette X, Ravaud P, Steinfeld S. , et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum 2004; 50 (04) 1270-1276
  • 312 Sankar V, Brennan MT, Kok MR. , et al. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004; 50 (07) 2240-2245
  • 313 Carsons SE, Vivino FB, Parke A. , et al. Treatment guidelines for rheumatologic manifestations of Sjögren's syndrome: use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain. Arthritis Care Res (Hoboken) 2017; 69 (04) 517-527